Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst
D E
DE
David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu
Breedveld
F C
FC
Kalden
J R
JR
Smolen
J S
JS
Burmester
G R
GR
Sieper
J
J
Emery
P
P
Keystone
E C
EC
Schiff
M H
MH
Mease
P
P
van Riel
P L C M
PL
Fleischmann
R
R
Weisman
M H
MH
Weinblatt
M E
ME
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D001171:Arthritis, Juvenile / Q000188:drug therapy; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000139:chemically induced; D000069283:Rituximab; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014376:Tuberculosis / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069594:Abatacept